Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTx-024 for muscle wasting in first-line non-small cell lung cancer
2011-001792-39Phase 3Completed
- Sponsor
- GTx
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cancer anorexia-cachexia syndrome (CACS), muscle atrophy and non-small cell lung cancer (NSCLC) comparing Ostarine arm with Placebo arm (2 arms). Primary endpoint: Physical function responder rate at Day 84 by stair climb power. Started Sep 2011; status: completed.
02
Drugs
enobosarm
03
Conditions
cancer anorexia-cachexia syndrome (CACS)muscle atrophynon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2011-001792-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001792-39.